Corcept to Present Phase 3 Platinum-Resistant Ovarian Cancer Survival Data May 29
Corcept will present Phase 3 ROSELLA overall survival subgroup analyses of relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer at ASCO on May 29. The combination was FDA approved in March 2026 and is included as a preferred NCCN regimen, with ~20,000 U.S. candidates annually.
1. ASCO Presentation Overview
Corcept will deliver an oral presentation at the ASCO Annual Meeting on May 29, showcasing overall survival subgroup analyses from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer. Data will focus on patient subgroups stratified by prior taxane use, comparing combination therapy to nab-paclitaxel monotherapy.
2. FDA Approval and Treatment Guidelines
Lifyorli (relacorilant) in combination with nab-paclitaxel received FDA approval in March 2026 for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer after one to three prior regimens. The regimen is now listed as a preferred option in clinical practice guidelines, targeting approximately 20,000 eligible patients in the U.S. annually.
3. Global Trial Collaboration and EMA Application
The ROSELLA study was conducted in collaboration with international cooperative oncology groups across North America, Europe, Asia-Pacific, Latin America and ANZGOG. Corcept has also submitted a Marketing Authorisation Application to the European Medicines Agency seeking approval for relacorilant in platinum-resistant ovarian cancer.